Skip to main content

DBV Technologies announces up to $307M financing to advance Viaskin Peanut program

Submitted by admin on
snippet

Clinical-stage biopharmaceutical company DBV Technologies (NASDAQ:DBVT) announced a financing of up to $306.9M (€284.5M), including gross proceeds of $125.5M (€116.3M) to be received upon closing and an aggregate of up to ($181.4M) (€168.2M) in gross proceeds if all the warrants are exercised.

Source
MSN/Seeking Alpha

Food allergy biotech DBV is running out of cash, with phase 3 trials underway

Submitted by admin on
snippet

DBV Technologies, a French biotech working on a treatment for food allergies, says it's running out of cash.

The disclosure came via a going concern note in the company’s fourth-quarter and full-year 2023 earnings report on Friday, with DBV saying it doesn’t have enough money to keep the lights on for a full 12 months.

Source
Fierce Biotech

Novartis Ends Phase III Peanut Allergy Trial in Another Flop for Potential Xolair Successor

Submitted by admin on
snippet

Novartis appears to be throwing in the towel on its Xolair-successor hopeful. The Swiss pharma’s Phase III peanut allergy trial for ligelizumab has been terminated, according to a ClinicalTrials.gov update Tuesday. 

Source
BioSpace

Years after $2B buyout, Nestlé ditches Aimmune's peanut allergy drug Palforzia

Submitted by admin on
snippet

After lackluster sales dampened the initial enthusiasm that came with a $2.1 billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia.

Nestlé has divested Palforzia to U.S.-based allergy specialist Stallergenes Greer for an undisclosed sum, the food giant said Tuesday.

Source
Fierce Pharma

Trial investigating peanut allergy immunotherapy hits final milestone

Submitted by admin on
snippet

A trial investigating desensitisation immunotherapy delivered as toothpaste for adults with peanut allergy reached a final milestone after Intrommune Therapeutics completed the last patient’s last visit.

The Phase I OMEGA clinical trial (NCT04603300) is a multi-centre, randomised, placebo-controlled double-blind study involving splitting 32 participants with peanut allergy into two groups to receive either an escalating dose of the company’s candidate INT301 or placebo.

Source
Clinical Trials Arena

IgGenix sprints to clinic with peanut allergy candidate and additional $40M

Submitted by admin on
snippet

A small, Eli Lilly-backed biotech has received $40 million on its way to the clinic with a self-administered injection for peanut allergies.

IgGenix unveiled a Series B round on Monday to support what CEO Jessica Grossman calls a “revolutionary” approach to preventing both food and non-food allergies, from dairy to dust to dogs.

Source
Endpoints

Nestlé to Sell Off Peanut Allergy Treatment, Not the Blockbuster They Hoped

Submitted by admin on
snippet

Nestlé announced Tuesday it will unload the world's only approved peanut allergy treatment just two years after acquiring the company that developed it. Potential patients must've found it easier to just not eat at Five Guys and Texas Roadhouse.

Source
Motley Fool

FDA slaps hold on DBV peanut allergy trial in call for protocol changes

Submitted by admin on
snippet

The FDA has grounded DBV Technologies’ latest phase 3 peanut allergy clinical trial before it even had a chance to take flight. Just weeks after DBV trumpeted the finalization of the protocol, the FDA has placed a partial clinical hold on the study and requested changes to the design of the study.

Source
Fierce Biotech

DBV patches up prospects with phase 3 win in infants with peanut allergies

Submitted by admin on
snippet

DBV Technologies has chalked up a win for its beleaguered peanut allergy patch candidate, hitting the primary endpoint in a phase 3 clinical trial in infants to send its battered share price past its prior high for 2022.

Source
Fierce Biotech

NICE backs Aimmune’s peanut allergy drug Palforzia for children

Submitted by admin on
snippet

Children in England with peanut allergies could be among the first in Europe to get access to Aimmune’s oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS England.

Source
Pharmaforum